Literature DB >> 26040486

Treatment and outcome of malignant giant cell tumor in the spine.

Huabin Yin1,2, Mo Cheng1, Bo Li1, Binbin Li3, Peng Wang4, Tong Meng1, Jing Wang1, Wang Zhou5, Wangjun Yan6, Jianru Xiao7.   

Abstract

Malignant giant cell tumor (MGCT) in the spine is extremely rare and there is little published information regarding this subject in the literature. We attempted to correlate different treatment options and outcomes over time. A retrospective study of patients with spinal MGCT who were surgically treated in our center between 2006 and 2012 was performed. Overall, three surgical management strategies, including subtotal resection, piecemeal total resection, and total en bloc spondylectomy were applied. Postoperative radiotherapy was carried out in 4 cases. Clinical data and efficacy of surgical treatment strategy were analyzed via chart review. A total of 14 patients with spinal MGCT were included in the study. Three cases were diagnosed as primary MGCT (PMGCT), while the other 11 patients were secondary MGCT (SMGCT). The mean follow-up period was 41 (range 3-75) months. Recurrence was found in 7 patients after surgery in our center, while distant metastasis and death occurred in 4 and 6 cases, respectively. MGCT of bone is always a high-grade sarcoma with a poor prognosis and complete excision, while also preserving neural function, is recommended. In our study, patients who underwent total en bloc spondylectomy had significantly lower local recurrence rate for MGCT in the spine.

Entities:  

Keywords:  Malignant giant cell tumor; Retrospective study; Spine; Total en bloc spondylectomy

Mesh:

Year:  2015        PMID: 26040486     DOI: 10.1007/s11060-015-1835-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  42 in total

1.  Secondary malignant giant cell tumor of the clivus: case report.

Authors:  Yasuo Sasagawa; Osamu Tachibana; Shunsuke Shiraga; Hisashi Takata; Eriko Kinoshita; Takayuki Nojima; Hideaki Iizuka
Journal:  Clin Neurol Neurosurg       Date:  2012-01-23       Impact factor: 1.876

2.  Late development of a malignant fibrous histiocytoma at the site of a giant cell tumor.

Authors:  E J Ortiz-Cruz; R H Quinn; J C Fanburg; A E Rosenberg; H J Mankin
Journal:  Clin Orthop Relat Res       Date:  1995-09       Impact factor: 4.176

Review 3.  De novo malignant transformation of giant cell tumor of bone.

Authors:  T Marui; T Yamamoto; H Yoshihara; M Kurosaka; K Mizuno; T Akamatsu
Journal:  Skeletal Radiol       Date:  2001-02       Impact factor: 2.199

4.  Sarcomatous degeneration of giant cell tumours.

Authors:  S Boriani; A Sudanese; N Baldini; P Picci
Journal:  Ital J Orthop Traumatol       Date:  1986-06

5.  Malignant giant cell tumor in the posterior fossa of a neonate.

Authors:  Petros N Karamanakos; Juha E Jaaskelainen; Irina Alafuzoff; Elina Pirinen; Ritva Vanninen; Sanna Silvennoinen; Ulla Sankilampi; Arto Immonen
Journal:  J Neurosurg Pediatr       Date:  2010-03       Impact factor: 2.375

6.  Factors affecting prognosis of patients with giant cell tumors of the mobile spine: retrospective analysis of 102 patients in a single center.

Authors:  Wei Xu; Xiang Li; Wending Huang; Yu Wang; Shuai Han; Su Chen; Leqin Xu; Xinghai Yang; Tielong Liu; Jianru Xiao
Journal:  Ann Surg Oncol       Date:  2012-10-25       Impact factor: 5.344

7.  Malignancy in giant cell tumor of bone.

Authors:  Franco Bertoni; Patrizia Bacchini; Eric L Staals
Journal:  Cancer       Date:  2003-05-15       Impact factor: 6.860

8.  Secondary malignant giant-cell tumor of bone. Clinicopathological assessment of nineteen patients.

Authors:  M G Rock; F H Sim; K K Unni; G A Witrak; F J Frassica; M F Schray; J W Beabout; D C Dahlin
Journal:  J Bone Joint Surg Am       Date:  1986-09       Impact factor: 5.284

9.  Surgical management of primary and metastatic sarcoma of the mobile spine.

Authors:  Ganesh Rao; Dima Suki; Indro Chakrabarti; Iman Feiz-Erfan; Milan G Mody; Ian E McCutcheon; Ziya Gokaslan; Shreyaskumar Patel; Laurence D Rhines
Journal:  J Neurosurg Spine       Date:  2008-08

10.  Giant-cell tumor of bone.

Authors:  M Campanacci; N Baldini; S Boriani; A Sudanese
Journal:  J Bone Joint Surg Am       Date:  1987-01       Impact factor: 5.284

View more
  10 in total

1.  Total neurological recovery after surgical decompression and treatment with denosumab of large unresectable spinal giant cell tumour expanding to mediastinum.

Authors:  Chirathit Anusitviwat; Monchai Ruangchainikom; Ekkapoj Korwutthikulrangsri; Werasak Sutipornpalangkul
Journal:  BMJ Case Rep       Date:  2022-05-12

Review 2.  Diagnosis and Treatment of Lumbar Giant Cell Tumor of the Spine: Update on Current Management Strategies.

Authors:  Andrew R Leggett; Ari R Berg; Heidi Hullinger; Joseph B Benevenia
Journal:  Diagnostics (Basel)       Date:  2022-03-30

3.  Prognostic Factors for Survival in Patients with Malignant Giant Cell Tumor of Bone: A Risk Nomogram Analysis Based on the Population.

Authors:  Xiaolong Zhu; Runzhi Huang; Peng Hu; Penghui Yan; Suna Zhai; Jie Zhang; Junwei Zhuang; Huabin Yin; Tong Meng; Daoke Yang; Zongqiang Huang
Journal:  Med Sci Monit       Date:  2021-02-17

4.  The Clinical Characteristics and Prediction Nomograms for Primary Spine Malignancies.

Authors:  Lei Zhou; Runzhi Huang; Ziheng Wei; Tong Meng; Huabin Yin
Journal:  Front Oncol       Date:  2021-02-26       Impact factor: 6.244

5.  Giant Cell Tumor of the Femoral Head: A Case Report and Review of the Literature.

Authors:  Hany Elbardesy; G A Sheridan; S Guerin
Journal:  J Orthop Case Rep       Date:  2021-05

6.  Construction, Validation, and Visualization of Two Web-Based Nomograms for Predicting Overall Survival and Cancer-Specific Survival in Elderly Patients with Primary Osseous Spinal Neoplasms.

Authors:  Yuexin Tong; Yuekai Cui; Liming Jiang; Yuan Zeng; Dongxu Zhao
Journal:  J Oncol       Date:  2022-04-04       Impact factor: 4.375

7.  Clinicopathological and histological analysis of secondary malignant giant cell tumors of bone without radiotherapy.

Authors:  Eiji Nakata; Hotaka Kawai; Tomohiro Fujiwara; Toshiyuki Kunisada; Hirofumi Inoue; Mashu Futagawa; Haruyoshi Katayama; Takuto Itano; Toshifumi Ozaki
Journal:  Oncol Lett       Date:  2022-07-19       Impact factor: 3.111

8.  Nomograms for prognostic factors of spinal giant cell tumor combining traditional clinical characteristics with inflammatory biomarkers after gross total resection.

Authors:  Jialin Li; Bo Li; Pingting Zhou; Jian Zhao; Zhipeng Wu; Xinghai Yang; Haifeng Wei; Tianrui Chen; Jianru Xiao
Journal:  Oncotarget       Date:  2017-09-22

9.  Recurrent giant cell tumour of the thoracic spine managed by total en bloc spondylectomy and denosumab therapy: a case report.

Authors:  Ping-Guo Duan; Yong-Hong Sheng; Chang-Hao Deng; Ben-Yu Tang; Hao-Qun Yao
Journal:  BMC Musculoskelet Disord       Date:  2020-02-15       Impact factor: 2.362

10.  Denosumab for Effective Tumor Size Reduction in Patients With Giant Cell Tumors of the Bone: A Systematic Review and Meta-Analysis.

Authors:  Josef Yayan
Journal:  Cancer Control       Date:  2020 Jul-Aug       Impact factor: 3.302

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.